EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis

Taro Kishi, Kenji Sakuma, Masakazu Hatano, Hiroyuki Uchida, Nakao Iwata

Journal of Affective Disorders · 2026-08 · 406 · 121675

DOI: 10.1016/j.jad.2026.121675 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Affective Disorders, 2026-08. Verfasst von Taro Kishi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan. Electronic address: tarok@fujita-hu.ac.jp. Hauptthemen laut MEDLINE: Psilocybin, Major Depressive Disorder, Hallucinogens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This systematic review and meta-analysis of six randomized controlled trials aimed to investigate the temporal changes in the efficacy and safety of psilocybin treatment for major depressive disorder (MDD). METHODS: Separate meta-analyses were conducted for standard-dose psilocybin (25 mg/session, or 20-30 mg/70 kg/session) and low-dose psilocybin (10 mg/session or 15.05 mg/70 kg/session) subgroups. Control conditions included placebo, waiting-list control, niacin, or psilocybin 1 mg. RESULTS: Standard-dose psilocybin was superior to control in reducing depressive symptoms (standardized mean difference [SMD]: -1.05; 95% confidence intervals [CIs]: -1.60 to -0.50, p = 0.0002, I2 = 75%, K = 4). Sensitivity analysis excluding studies with waiting-list controls supported the superiority of standard-dose psilocybin compared with control without considerable heterogeneity (SMD: -0.70; 95% CI: -1.03 to -0.36, p < 0.0001, I2 = 43%, K = 2). This sensitivity analysis included two double-blind trials that incorporated manualized psilocybin-assisted psychotherapy. Compared with controls, standard-dose psilocybin was associated with higher response (risk ratio [RR]: 2.34; 95% CI: 1.52-3.60, p = 0.0001, I2 = 0%) and remission rates at 2-3 weeks post-treatment (RR: 3.38; 95% CI: 1.88-6.08, p < 0.0001, I2 = 0%), with response rate at 6-12 weeks post-treatment (RR: 2.61; 95% CI: 1.45-4.71, p = 0.001, I2 = 0%). Moreover, standard-dose psilocybin was related to lower all-cause discontinuation compared with control (RR: 0.39; 95% CI: 0.18-0.87, p = 0.02, I2 = 0%). Standard-dose psilocybin was associated with a higher incidence of headache (RR: 2.06; 95% CI: 1.11-3.81, p = 0.02, I2 = 57%) and nausea within 1-9 days post-treatment (RR: 10.20; 95% CI: 3.80-27.39, p < 0.0001, I2 = 0%) compared with the control; however, these symptoms resolved after this period. Low-dose psilocybin demonstrated no superior efficacy compared with the control group. CONCLUSIONS: This meta-analysis indicates that standard-dose psilocybin may represent a promising therapeutic option for MDD treatment. Nonetheless, future research should address the considerable methodological heterogeneity across current trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsilocybinMajor Depressive DisorderHallucinogensHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

DepressionMeta-analysisPsilocybinRandomized controlled trialSystematic review

Substanzen

PsilocybinHallucinogens

Autor:innen und Institutionen

  • Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan. Electronic address: tarok@fujita-hu.ac.jp.
  • Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.
  • Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, 47…
  • Department of Neuropsychiatry, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kishi, T., Sakuma, K., Hatano, M., Uchida, H., & Iwata, N. (2026). Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. Journal of Affective Disorders, 406, 121675. https://doi.org/10.1016/j.jad.2026.121675

Vancouver

Kishi T, Sakuma K, Hatano M, Uchida H, Iwata N. Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis. Journal of Affective Disorders. 2026;406:121675. doi:10.1016/j.jad.2026.121675

BibTeX
@article{Kishi2026,
  author = {Kishi, Taro and Sakuma, Kenji and Hatano, Masakazu and Uchida, Hiroyuki and Iwata, Nakao},
  title = {Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {406},
  pages = {121675},
  doi = {10.1016/j.jad.2026.121675}
}
Kostenlos starten →